Logo image of ANL

ADLAI NORTYE LTD-ADR (ANL) Stock Fundamental Analysis

NASDAQ:ANL - Nasdaq - US00704R1095 - ADR - Currency: USD

1.5  -0.01 (-0.66%)

Fundamental Rating

1

ANL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. ANL has a bad profitability rating. Also its financial health evaluation is rather negative. ANL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANL had negative earnings in the past year.
In the past year ANL has reported a negative cash flow from operations.
ANL had negative earnings in each of the past 5 years.
In the past 5 years ANL always reported negative operating cash flow.
ANL Yearly Net Income VS EBIT VS OCF VS FCFANL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -72.78%, ANL is doing worse than 64.87% of the companies in the same industry.
With a Return On Equity value of -203.53%, ANL is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -72.78%
ROE -203.53%
ROIC N/A
ROA(3y)-79.22%
ROA(5y)-90.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANL Yearly ROA, ROE, ROICANL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

ANL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANL Yearly Profit, Operating, Gross MarginsANL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANL has about the same amount of shares outstanding.
Compared to 1 year ago, ANL has a worse debt to assets ratio.
ANL Yearly Shares OutstandingANL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ANL Yearly Total Debt VS Total AssetsANL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -9.44, we must say that ANL is in the distress zone and has some risk of bankruptcy.
ANL has a Altman-Z score of -9.44. This is in the lower half of the industry: ANL underperforms 71.86% of its industry peers.
A Debt/Equity ratio of 1.05 is on the high side and indicates that ANL has dependencies on debt financing.
ANL's Debt to Equity ratio of 1.05 is on the low side compared to the rest of the industry. ANL is outperformed by 77.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.05
Debt/FCF N/A
Altman-Z -9.44
ROIC/WACCN/A
WACCN/A
ANL Yearly LT Debt VS Equity VS FCFANL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

ANL has a Current Ratio of 1.41. This is a normal value and indicates that ANL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ANL (1.41) is worse than 82.26% of its industry peers.
A Quick Ratio of 1.41 indicates that ANL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.41, ANL is doing worse than 81.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
ANL Yearly Current Assets VS Current LiabilitesANL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.51% over the past year.
EPS 1Y (TTM)78.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.26% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.09%
EPS Next 2Y26.13%
EPS Next 3Y35.51%
EPS Next 5Y30.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANL Yearly Revenue VS EstimatesANL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ANL Yearly EPS VS EstimatesANL Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANL Price Earnings VS Forward Price EarningsANL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANL Per share dataANL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ANL's earnings are expected to grow with 35.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.13%
EPS Next 3Y35.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADLAI NORTYE LTD-ADR

NASDAQ:ANL (7/17/2025, 8:02:42 PM)

1.5

-0.01 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30
Earnings (Next)08-08 2025-08-08
Inst Owners0.18%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap55.35M
Analysts45
Price Target9.18 (512%)
Short Float %0.01%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)60.87%
EPS NY rev (3m)60.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.17
P/tB 2.18
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.78%
ROE -203.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.22%
ROA(5y)-90.58%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z -9.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)50.59%
Cap/Depr(5y)120.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.51%
EPS Next Y59.09%
EPS Next 2Y26.13%
EPS Next 3Y35.51%
EPS Next 5Y30.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.53%
OCF growth 3YN/A
OCF growth 5YN/A